Stock Analiz

Ptc Therapeutics, Inc. (PTCT) financials: revenue, earnings and cash flow

Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026

Summary

Ptc Therapeutics’s revenue went from $83M in fiscal 2016 to $1.7B in fiscal 2025, growth of about 40.2% a year.

Net income in fiscal 2025 was $683M, a net margin of 39.4%; the highest of the period.

Over the twelve months to September 30, 2026, revenue was $1.2B and net income -$106M.

Free cash flow was $702M in fiscal 2025 and positive in 1 of the 10 years shown.

The diluted share count rose 159% over the period (dilution).

Revenue, profit and cash flow by year

Revenue
2016: $83M162017: $194M172018: $265M182019: $307M192020: $381M202021: $539M212022: $699M222023: $938M232024: $807M242025: $1.7B25$1.7B
Net income
2016: -$142M162017: -$79M172018: -$128M182019: -$252M192020: -$438M202021: -$524M212022: -$559M222023: -$627M232024: -$363M242025: $683M25$683M
Free cash flow
2016: -$105M162017: -$13M172018: -$35M182019: -$112M192020: -$212M202021: -$280M212022: -$389M222023: -$187M232024: -$114M242025: $702M25$702M
EPS (diluted)
2016: $-4.17162017: $-2.02172018: $-2.75182019: $-4.27192020: $-6.64202021: $-7.43212022: $-7.79222023: $-8.37232024: $-4.73242025: $7.7825$7.78

Income statement

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$1.2B$1.7B$807M$938M$699M$539M$381M$307M$265M$194M$83M
Gross profit———————$295M$252M$190M$83M
Operating income$148M$867M-$303M-$440M-$447M-$374M-$432M-$241M-$116M-$64M-$132M
Net income-$106M$683M-$363M-$627M-$559M-$524M-$438M-$252M-$128M-$79M-$142M
EPS (diluted)$-1.40$7.78$-4.73$-8.37$-7.79$-7.43$-6.64$-4.27$-2.75$-2.02$-4.17
R&D$439M$455M$534M$667M$651M$541M$478M$257M$172M$117M$118M
Revenue growth—+114.5%−14.0%+34.2%+29.8%+41.4%+24.0%+16.0%+36.2%+135.0%+125.0%

Cash flow

Fiscal yearTTM2025202420232022202120202019201820172016
Operating cash flow$10M$711M-$108M-$158M-$357M-$251M-$194M-$99M-$28M-$10M-$104M
Capital spending-$8M-$9M-$7M-$28M-$32M-$28M-$18M-$14M-$7M-$3M-$2M
Free cash flow$2M$702M-$114M-$187M-$389M-$280M-$212M-$112M-$35M-$13M-$105M
Dividends paid—$0$0$0$0$0$0$0$0$0$0
Buybacks———————————
Stock-based pay$89M$75M$75M$102M$110M$104M$70M$42M$33M$31M$35M

Balance sheet

Fiscal yearTTM2025202420232022202120202019201820172016
Cash—$1.9B$1.1B$877M$411M$773M$1.1B$687M$228M$191M$232M
Debt—$393M$371M$395M$682M$512M$396M$328M$164M$145M$98M
Equity—-$205M-$1.1B-$819M-$347M$1M$482M$594M$351M$156M$120M
Total assets—$2.9B$1.7B$1.9B$1.7B$1.9B$2.2B$1.6B$1.1B$392M$269M
Shares (diluted)83M88M77M75M72M70M66M59M47M39M34M

Margins and returns

Fiscal yearTTM2025202420232022202120202019201820172016
Gross margin———————96.0%95.2%97.7%100.0%
Operating margin12.8%50.1%-37.5%-46.9%-64.0%-69.5%-113.4%-78.6%-43.7%-33.1%-159.7%
Net margin-9.2%39.4%-45.0%-66.8%-80.0%-97.3%-115.1%-82.0%-48.4%-40.6%-171.8%
FCF margin0.2%40.6%-14.1%-19.9%-55.6%-51.9%-55.6%-36.6%-13.1%-6.8%-127.4%
ROIC—453.4%——-127.1%-57.6%-38.9%-20.7%-22.5%-16.9%-47.9%
ROE—-332.5%33.1%76.5%161.1%-36432.6%-90.9%-42.3%-36.5%-50.5%-118.8%

Frequently asked questions

What is Ptc Therapeutics’s annual revenue?

$1.7B in fiscal 2025 and $1.2B over the twelve months to September 30, 2026.

How much profit does Ptc Therapeutics make?

Net income was $683M in fiscal 2025 (net margin 39.4%).

Is Ptc Therapeutics’s revenue growing?

Yes: revenue rose 114.5% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.